Chronic Immune Thrombocytopenia
Conditions
Interventions
Single Arm:eltrombopag treatment
Sponsors
Shanghai Sixth People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Main Inclusion criteria: 1. Patients diagnosed with immune thrombocytopenia and eligible for Revolade [Turkey: eltrombopag] treatment according to the market authorization in the country and the investigators judgement; 2. cITP patients startingon eltrombopag treatment (patients who started treatment in the current treatment cycle up to 12 weeks prior to study enrollment are also eligible);Previous discontinued treatment cycles of eltrombopag are permitted as long as the time period between the last dose in the previous cycle and the first dose within the CITE study-relevant course is at least 12 weeks; 3. Prior treatment with romiplostim is allowed; 4. Male or female, adults = 18 years; 5. Written informed consent.
Exclusion criteria
Exclusion criteria: Main Exclusion Criteria: 1. Any contraindication listed in the local market authorization/SmPC; 2. Patients with active alcohol or drug addiction that would interfere with their ability; 3. According to the investigators opinion, the patient is an unlikely candidate to obtain longterm follow-up information for any reasons such as unavailability or severe concomitant illnesses; 4. Patients participating in any interventional clinical trial at start of this clinical study; 5. For the indication of ITP also non-interventional studies other than CITE are excluded; 6. No pediatric ITP patients (<18 years) will be included into this NIS; 7. Other indications for eltrombopag such as for patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, or Severe Aplastic Anemia (SAA) are not in scope and will not be enrolled in this NIS.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment duration and adherence;Efficacy (hematological and clinical); | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment algorithm in cITP and Utilization;Quality of life: fatigue;Safety and tolerability; | — |
Countries
China
Contacts
Public ContactChunkang Chang
The Sixth People's Hospital of Shanghai
Outcome results
None listed